Evidence map›Paper›PMID 26962216›Full record

ArticleJournal of virology2016

Human Papillomavirus E2 Regulates SRSF3 (SRp20) To Promote Capsid Protein Expression in Infected Differentiated Keratinocytes.

T Klymenko, H Hernandez-Lopez, A I MacDonald, J M Bodily, S V Graham

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 44 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Viral Modulation of Host Splicing.Annual review of virology · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Alternative splicing in the genome of HPV and its regulation.Frontiers in cellular and infection microbiology · 2024
    Review
  12. Article
  13. Article
  14. Oncogenic SRSF3 in health and diseases.International journal of biological sciences · 2023
    Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

T KlymenkoMRC-University of Glasgow Centre for Virus Research, Institute of Infection, Immunity, and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom.
H Hernandez-LopezMRC-University of Glasgow Centre for Virus Research, Institute of Infection, Immunity, and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom.
A I MacDonaldMRC-University of Glasgow Centre for Virus Research, Institute of Infection, Immunity, and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom.
J M BodilyLouisiana State University Health Sciences Center, Department of Microbiology and Immunology, Shreveport, Louisiana, USA.
S V GrahamMRC-University of Glasgow Centre for Virus Research, Institute of Infection, Immunity, and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom sheila.graham@gla.ac.uk.
MRC University of Glasgow Centre for Virus Research · GBLouisiana State University Health Sciences Center Shreveport · US

Funding

COBRE Center for Molecular and Tumor VirologyP30GM110703 · NIGMS · LOUISIANA STATE UNIV HSC SHREVEPORT · PI SAPP, MARTIN · 2014 to 2018
$4.8M
ThThe Role of Epithelial-Stromal Communication in the Human Papillomavirus Type 16 Life CycleR01AI118904 · NIAID · LOUISIANA STATE UNIV HSC SHREVEPORT · PI BODILY, JASON M · 2015 to 2019
$1.6M
Genetic analysis of Human Papillomavirus E2 proteinF32CA123814 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI BODILY, JASON M · 2006 to 2007
$95k
Medical Research Council MC_UU_12014/3NCI NIH HHS F32 CA123814NIAID NIH HHS R01 AI118904NIGMS NIH HHS P30 GM110703Wellcome TrustWellcome Trust WTD004098
6 · The paper itself

Abstract

unlabelledThe human papillomavirus (HPV) life cycle is tightly linked to differentiation of the infected epithelial cell, suggesting a sophisticated interplay between host cell metabolism and virus replication. Previously, we demonstrated in differentiated keratinocytes in vitro and in vivo that HPV type 16 (HPV16) infection caused increased levels of the cellular SR splicing factors (SRSFs) SRSF1 (ASF/SF2), SRSF2 (SC35), and SRSF3 (SRp20). Moreover, the viral E2 transcription and replication factor that is expressed at high levels in differentiating keratinocytes could bind and control activity of the SRSF1 gene promoter. Here, we show that the E2 proteins of HPV16 and HPV31 control the expression of SRSFs 1, 2, and 3 in a differentiation-dependent manner. E2 has the greatest transactivation effect on expression of SRSF3. Small interfering RNA depletion experiments in two different models of the HPV16 life cycle (W12E and NIKS16) and one model of the HPV31 life cycle (CIN612-9E) revealed that only SRSF3 contributed significantly to regulation of late events in the virus life cycle. Increased levels of SRSF3 are required for L1 mRNA and capsid protein expression. Capsid protein expression was regulated specifically by SRSF3 and appeared independent of other SRSFs. Taken together, these data suggest a significant role of the HPV E2 protein in regulating late events in the HPV life cycle through transcriptional regulation of SRSF3 expression. IMPORTANCE: Human papillomavirus replication is accomplished in concert with differentiation of the infected epithelium. Virus capsid protein expression is confined to the upper epithelial layers so as to avoid immune detection. In this study, we demonstrate that the viral E2 transcription factor activates the promoter of the cellular SRSF3 RNA processing factor. SRSF3 is required for expression of the E4(^)L1 mRNA and so controls expression of the HPV L1 capsid protein. Thus, we reveal a new dimension of virus-host interaction crucial for production of infectious virus. SRSF proteins are known drug targets. Therefore, this study provides an excellent basis for developing strategies to regulate capsid protein production in the infected epithelium and the production of new virions.

Indexed as

Capsid ProteinsCell DifferentiationDNA-Binding ProteinsGene Expression Regulation, ViralHost-Pathogen InteractionsHuman papillomavirus 16Human papillomavirus 31HumansKeratinocytesLife Cycle StagesOncogene Proteins, ViralPapillomaviridaeRNA, MessengerSerine-Arginine Splicing FactorsTranscription FactorsVirus ReplicationCapsid ProteinsDNA-Binding Proteinsoncogene protein E2, Human papillomavirus type 1Oncogene Proteins, ViralRNA, MessengerSerine-Arginine Splicing FactorsSRSF1 protein, humanSRSF2 protein, humanSRSF3 protein, humanTranscription Factors

Identifiers

PMID26962216
PMCPMC4859725
OpenAlexW2293687212

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.